Table 4 The demographics related to all analyzed conditions in the Czech Republic.
Czech Republic | ||||||
|---|---|---|---|---|---|---|
2017 | 2018 | 2019 | 2020 | 2021 | ||
TBI | ||||||
Age (median, IQR) | 57.5 (43–71.75) | 63.0 (39.5–74.0) | 64.5 (39.25–75.0) | 62.5 (40.75–71.75) | 59.0 (43.0–68.75) | |
Sex (male) | 48 (64.9%) | 51 (75.0%) | 69 (70.4%) | 36 (75.0%) | 44 (71.0%) | |
TBI grade | 3.0 (2.0–3.0) | 3.0 (1.0–3.0) | 3.0 (1.0–3.0) | 3.0 (1.0–3.0) | 2.0 (1.0–3.0) | |
Initial GCS | 8.0 (3.0–13.75) | 5.0 (3.0–13.0) | 6.0 (3.0–13.0) | 6.5 (3.0–12.0) | 9.5 (4.25–14.0) | |
GOSE (median, IQR) | 4.0 (2.0–6.0) | 3.0 (2.0–5.0) | 3.0 (2.0–5.0) | 3.0 (2.0–6.0) | 3.5 (2.0–6.0) | |
cSDH | ||||||
Age | 73.0 (62.5–79.5) | 71.5 (63.25–80.75) | 71.5 (64.0–77.25) | 75.0 (71.0–81.0) | 75.0 (69.0–80.0) | |
Sex (male) | 70 (80.5%) | 84 (76.4%) | 57 (67.9%) | 37 (69.8%) | 45 (61.6%) | |
Initial GCS | 15.0 (14.0–15.0) | 15.0 (14.0–15.0) | 15.0 (14.0–15.0) | 15.0 (14.0–15.0) | 15.0 (14.0–15.0) | |
GOSE | 7.0 (5.0–7.5) | 7.0 (5.0–8.0) | 7.0 (5.0–8.0) | 7.0 (4.0–8.0) | 7.0 (6.0–7.25) | |
SAH and Other Vascular Lesions | ||||||
Age | 60.0 (50.5–68.5) | 60.0 (51.0–67.5) | 64.0 (51.0–71.0) | 62.0 (48.5–71.0) | 58.0 (47.5–69.5) | |
Sex (male) | 28 (47.5%) | 32 (54.2%) | 29 (43.9%) | 28 (44.4%) | 34 (58.6%) | |
Initial GCS | 14.0 (11.0–15.0) | 14.0 (6.5–15.0) | 14.5 (10.0–15.0) | 14.0 (7.5–15.0) | 15.0 (12.0–15.0) | |
Aneurysms N (%) | 21 (39.6%) | 34 (50%) | 33 (55.9%) | 31 (52.5%) | 24 (40.7%) | |
Hunt&Hess Classification | 1.0 (0.0–3.25) | 2.0 (0.0–3.0) | 2.0 (0.0–3.0) | 2.0 (1.0–4.0) | 1.0 (0.0–3.0) | |
Fisher Classification | 2.0 (0.0–4.0) | 3.0 (0.0–4.0) | 3.0 (0.0–4.0) | 3.0 (0.0–4.0) | 3.0 (1.0–4.0) | |
Last mRS | 2.0 (1.0–5.0) | 2.0 (0.0–5.0) | 2.0 (1.0–5.0) | 3.0 (1.0–5.0) | 2.0 (1.0–3.0) | |
Timing of Aneurysm Treatment | 2.0 (1.0–2.0) | 1.0 (1.0–2.0) | 2.0 (2.0–4.0) | 1.0 (1.0–3.0) | 1.0 (1.0–1.0) | |
GOSE | 6.0 (3.0–7.5) | 6.0 (3.0–7.0) | 5.0 (3.0–7.0) | 4.0 (3.0–7.0) | 6.0 (4.5–7.0) | |
Spine Lesions | ||||||
Age | 58.0 (45–68) | 57.0 (44.0–70.0) | 62.0 (42.5–71.5) | 55.0 (44.0–69.0) | 58.4 (45.0–69.25) | |
Sex (male) | 105 (60.0%) | 93 (66.9%) | 87 (64.4%) | 104 (68.0%) | 124 (59.6%) | |
Timing from Symptoms to Surgery | 3.0 (1.0–4.0) | 3.0 (1.0–4.0) | 3.0 (1.5–4.0) | 3.0 (1.0–4.0) | 4.0 (2.0–5.0) | |
GOSE | 7.0 (6.0–8.0) | 6.0 (5.0–7.0) | 6.0 (4.0–7.0) | 6.5 (5.0–7.0) | 7.0 (5.75–8.0) | |
Acute Hydrocephalus | ||||||
Age | 17.0 (1.0–55.0) | 41.0 (7.25–67.0) | 47.0 (3.5–64.5) | 56.0 (17.0–70.0) | 39.0 (15.0–81.0) | |
Sex (male) | 32 (60.4%) | 19 (45.2%) | 23 (39.0%) | 20 (44.4%) | 25 (59.5%) | |
New Onset of Acute Hydrocephalus | 29 (54.7%) | 25 (59.5%) | 34 (57.6%) | 31 (68.9%) | 24 (57.1%) | |
GOSE | 6.0 (4.0–7.0) | 6.0 (4.0–8.0) | 5.0 (3.0–7.0) | 5.0 (3.0–7.0) | 6.0 (5.0–8.0) | |
Tumors and Other Intracranial Lesions | ||||||
Age | 58.5 (41.25–70.75) | 55.0 (43.0–68.0) | 61.0 (48.75–70.0) | 59.0 (46.0–70.0) | 61.0 (46.0–71.75) | |
Sex (male) | 72 (52.2) | 68 (51.1%) | 69 (48.6%) | 67 (44.4%) | 64 (40.5%) | |
Seizures | 23 (16.7%) | 21 (15.8%) | 23 (16.2%) | 28 (18.5%) | 24 (15.2%) | |
Any Focal Neurological Deficit | 96 (70.6%) | 98 (73.7%) | 99 (69.7%) | 101 (66.9%) | 111 (70.3%) | |
GOSE | 6.0 (4.0–7.0) | 6.0 (4.0–7.0) | 5.0 (3.0–7.0) | 6.0 (5.0–7.0) | 6.0 (5.0–7.0) | |
